ADRB2

(redirected from beta-2 adrenergic receptor)

ADRB2

A gene on chromosome 5q31-q32 that encodes beta-2-adrenergic receptor, a member of the G protein-coupled receptor superfamily, which mediates catecholamine-induced activation of adenylate cyclase. ADRB2 binds epinephrine with a 30-fold greater affinity than it does with norepinephrine.
Mentioned in ?
References in periodicals archive ?
and PHILADELPHIA, March 16 /PRNewswire/ -- Data presented today by GlaxoSmithKline showed that genetic differences at the site of the beta-2 adrenergic receptor gene in asthma patients did not lead to different responses to Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) or Serevent Diskus(R) (salmeterol xinofoate inhalation powder).
Past prospective clinical trials have found that the use of short-acting beta-agonists, such as albuterol, were linked to worse outcomes in patients with asthma with the Arg/Arg genotype of the beta-2 adrenergic receptor gene.
8 Association between Beta-1 and Beta-2 Adrenergic Receptor Polymorphism and Beta-blocker Therapy in Korean Heart Failure
New Findings Published in Molecular Cancer Therapeutics Demonstrate Novel and Selective Synergy for Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Combination with Standard of Care Drugs
In the article entitled, "Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening," by Rickles, et.
Nasdaq: DDDP) today reported that its G protein-coupled receptor (GPCR) crystallization project has not succeeded, as previously believed, in producing crystals and X-ray data required to determine the structure of the beta-2 adrenergic receptor, a drug target GPCR.
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.
Preclinical Data on A2A and Beta-2 Adrenergic Receptor Agonist Programs in B-Cell Malignancies To Be Presented
Data presented during the conference included a review of the Company's adenosine A2A and beta-2 adrenergic receptor agonism programs; novel, selective and synergistic multiple myeloma targets that have demonstrated synergy with several drug classes and broad activity in multiple myeloma and other B-cell malignancy tumor cell lines.
Abstract #384, Monday, December 8, 2008: 12:15 PM, "Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel, Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening", Rickles, et al.
Binding to beta-1 and beta-2 adrenergic receptors was investigated using 50 pM final concentration of the non-selective beta receptor radioligand [125 I]iodocynanopindolol in the presence or absence of varying cold beta receptor ligand concentrations in membranes prepared from explanted human left ventricular myocardium.
MN-221 is designed to help relax uterine smooth muscle via the selective stimulation of beta-2 adrenergic receptors.